Advocacy update
The Advocacy Update is a weekly advocacy newsletter that provides brief political and regulatory news and AADA’s advocacy activity updates. Delivered weekly to members’ email, Advocacy Update provides news that affects dermatology including federal and state policy, legislation and political action, and economic and regulatory affairs. In addition, AAD members receive special news alerts throughout the year when advocacy news breaks.
Recent issues
Following relentless advocacy by AADA, the FDA approved significant modifications to the iPLEDGE program.
The AADA urged Washington legislators to support legislation that would require truth in advertising and transparency on medical credentials.
The AADA urges Congress to back clinician-led data registries and relieve administrative burdens as it contemplates a successor to MIPS.
The AADA nominated and CMS selected AADA board member Alina Bridges, DO, FAAD, to serve as an expert on CMS’s Medicare CLDT Advisory Panel.
The AADA urges New York to pass legislation requiring medspas to clearly disclose to consumers that they are not licensed to perform medical procedures.
The AADA applauded the FDA for proposing to permit use of a new sunscreen ingredient, bemotrizinol (BEMT).
Advocacy news alerts
FDA finally confirms iPLEDGE changes long advocated for by AADA.
The FDA has proposed the first new sunscreen active ingredient, called BEMT, in 26 years.
See our update on the 2026 Final Rule for the Medicare Physician Fee Schedule.
See past issues of the weekly Advocacy Update newsletter.
